Merck & Co., Inc. (NYSE:MRK) Trading Up 0.9% - What's Next?

Merck & Co., Inc. (NYSE:MRK - Get Free Report) shares shot up 0.9% on Monday . The company traded as high as $83.61 and last traded at $83.51. 3,158,685 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 11,874,962 shares. The stock had previously closed at $82.74.

Analysts Set New Price Targets

MRK has been the subject of a number of recent research reports. Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. BMO Capital Markets dropped their target price on shares of Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a report on Wednesday, February 5th. UBS Group cut their price objective on Merck & Co., Inc. from $125.00 to $120.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Citigroup cut their price target on Merck & Co., Inc. from $125.00 to $115.00 and set a "buy" rating for the company in a report on Wednesday, February 5th. Finally, TD Securities lowered shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and decreased their target price for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Twelve equities research analysts have rated the stock with a hold rating, eight have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and an average price target of $111.13.

Merck & Co., Inc. Trading Up 0.2 %

The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $209.15 billion, a P/E ratio of 12.34, a price-to-earnings-growth ratio of 0.77 and a beta of 0.40. The company has a fifty day simple moving average of $87.05 and a two-hundred day simple moving average of $95.03.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same quarter in the prior year, the firm posted $2.07 EPS. The firm's revenue for the quarter was down 1.6% compared to the same quarter last year. On average, sell-side analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 7th. Investors of record on Monday, March 17th were given a dividend of $0.81 per share. The ex-dividend date was Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.91%. Merck & Co., Inc.'s dividend payout ratio is 47.16%.

Merck & Co., Inc. announced that its Board of Directors has approved a stock buyback plan on Tuesday, January 28th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Insider Buying and Selling at Merck & Co., Inc.

In related news, insider Cristal N. Downing sold 2,361 shares of the business's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total transaction of $209,562.36. Following the transaction, the insider now owns 7,085 shares in the company, valued at $628,864.60. The trade was a 24.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Inge G. Thulin purchased 2,833 shares of Merck & Co., Inc. stock in a transaction on Thursday, February 6th. The stock was bought at an average price of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares of the company's stock, valued at approximately $258,837.25. This trade represents a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.09% of the company's stock.

Institutional Investors Weigh In On Merck & Co., Inc.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Midwest Capital Advisors LLC bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $26,000. Barnes Dennig Private Wealth Management LLC bought a new position in shares of Merck & Co., Inc. in the first quarter valued at approximately $27,000. Financial Life Planners purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at $28,000. Noble Wealth Management PBC purchased a new position in Merck & Co., Inc. during the 4th quarter worth $28,000. Finally, Halbert Hargrove Global Advisors LLC purchased a new position in Merck & Co., Inc. during the 4th quarter worth $28,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.